FO_INSIGHT_2_RESUBMISSION_SUPPL_BLINDED_v1.0.docx (19.23 kB)
Supplementary Table 1 - FON-2021-1406 - INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
dataset
posted on 2021-12-17, 12:23 authored by Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye Mun Tho, Xiuning Le, Julien Mazieres, How Soon Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl Maria Schumacher, Niki Karachaliou, Yi-Long Wu|
Table S1. Clinical outcomes with first-, second- and third-generation EGFR TKIs received as first-line therapy in randomized controlled clinical trials of EGFR TKIs in EGFR-mutant advanced NSCLC [1–22] EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TKI: tyrosine kinase inhibitor.
|
